News
04-06-2009, 05:11 AM
Pfizer Inc announced the discontinuation of one of its Phase 3 studies based on statistical assessment for futility: the SUN 1107 Phase 3 study of Sutent® (sunitinib malate) in advanced breast cancer. SUN 1107 evaluated single-agent sunitinib versus single-agent capecitabine for the treatment of a broad range of patients with advanced breast cancer after failure of standard treatment.
More... (http://www.medicalnewstoday.com/articles/145204.php)
More... (http://www.medicalnewstoday.com/articles/145204.php)